FKBP-12–calcineurin complex (FKBP12-CaN) (FKBP12-CaN)

The FKBP-12–calcineurin complex is a critical signaling assembly involved in the activation of the adaptive immune system. It forms when an immunosuppressive drug, such as pimecrolimus, binds to the 12 kDa FK506-binding protein (FKBP-12), creating a composite surface that high-affinity binds to calcineurin, a calcium-calmodulin-dependent phosphatase [StatPearls: Pimecrolimus, PubChem: Pimecrolimus]. This binding sterically hinders calcineurin's active site, preventing it from dephosphorylating the Nuclear Factor of Activated T-cells (NFAT) [UniProt: PPP3CA]. Without dephosphorylation, NFAT cannot translocate from the cytoplasm to the nucleus, which effectively halts the transcription of pro-inflammatory cytokines like interleukin-2 and interferon-gamma [PubMed: 12473381]. This pathway is a primary target for treating inflammatory disorders, particularly atopic dermatitis, as it allows for the selective modulation of T-cell-mediated inflammation [StatPearls: Pimecrolimus]. While highly effective, long-term use of drugs targeting this complex requires monitoring due to potential risks of localized infections and theoretical concerns regarding skin malignancy [StatPearls: Pimecrolimus].

Other names

CalcineurinProtein phosphatase 2BPP2BFKBP12-pimecrolimus-calcineurin complexFKBP1A-PPP3CA complexFK506-binding protein 12–calcineurin complex

Pimecrolimus binds to the cytosolic protein FKBP-12 to form a drug-protein complex that subsequently binds to and inhibits the phosphatase activity of calcineurin, preventing the dephosphorylation and nuclear translocation of the Nuclear Factor of Activated T-cells (NFAT) and thereby blocking the transcription of pro-inflammatory cytokines.